We found that in contrast to oncogenic β-TrCP1 and SKP2, FBXW2 acts as a tumour suppressor to inhibit growth and survival of lung cancer cells, and high FBXW2 expression predicts a better patient survival. Here, BTRC is linked to lung carcinoma.